About SalvaRx Group Plc (LON:3LEG)
SalvaRx Group plc, formerly 3Legs Resources plc, is an investing company. The Company is engaged in drug discovery and development, focused on immune-oncology. The Company's segment is appraisal of investment targets meeting the Company's investment policy. The Company is focused on evaluation and assessment of investment opportunities in line with the investment policy. Its product is IMM60. It expects the study to evaluate approximately three treatment groups: a control arm using the standard of care (an anti-programmed death (PD)-1 therapy), a trial arm using iOX Therapeutics Ltd's drug (IMM60), and a third arm that will test the combination of IMM60 and an anti-PD1 therapy. 3Legs Management Services US LLC is the subsidiary of the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:3LEG
- CUSIP: N/A
- Web: www.3legsresources.com/
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Return on Equity: -168.36%
- Return on Assets: -64.33%
Frequently Asked Questions for SalvaRx Group Plc (LON:3LEG)
What is SalvaRx Group Plc's stock symbol?
SalvaRx Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "3LEG."
Who are some of SalvaRx Group Plc's key competitors?
Some companies that are related to SalvaRx Group Plc include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), BIOVERATIV INC (BIVV), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH) and Halozyme Therapeutics (HALO).
Who are SalvaRx Group Plc's key executives?
SalvaRx Group Plc's management team includes the folowing people:
- Kamlesh Rameshbhai Parmar, Chief Executive Officer, Executive Director
- Frances Morris-Jones, Business Development Director
- Alexander Fraser, Chief Financial Officer, Director
- Richard J. Armstrong, Non-Executive Chairman of the Board
- Timothy John Crommelin Eggar, Non-Executive Independent Chairman of the Board
- Gregory H. Bailey M.D., Non-Executive Director
- James Mellon, Non-Executive Director
How do I buy SalvaRx Group Plc stock?
Shares of SalvaRx Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is SalvaRx Group Plc's stock price today?
MarketBeat Community Rating for SalvaRx Group Plc (LON 3LEG)MarketBeat's community ratings are surveys of what our community members think about SalvaRx Group Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of SalvaRx Group Plc stock can currently be purchased for approximately GBX 0.32.
Consensus Ratings for SalvaRx Group Plc (LON:3LEG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for SalvaRx Group Plc (LON:3LEG)
Analysts' Ratings History for SalvaRx Group Plc (LON:3LEG)
(Data available from 10/21/2015 forward)
|2/2/2016||Northland Securities||Reiterated Rating||Corporate|
Earnings History for SalvaRx Group Plc (LON:3LEG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for SalvaRx Group Plc (LON:3LEG)
Current Year EPS Consensus Estimate: $-3.00 EPS
Dividend History for SalvaRx Group Plc (LON:3LEG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for SalvaRx Group Plc (LON:3LEG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for SalvaRx Group Plc (LON:3LEG)
Latest Headlines for SalvaRx Group Plc (LON:3LEG)
Loading headlines, please wait.
SalvaRx Group Plc (3LEG) Chart for Saturday, October, 21, 2017